Adverse effects of venlafaxine therapy and risk factors for their occurrence
Pharmacotherapy in Psychiatry and Neurology · 2019
DOI: 10.33450/fpn.2019.01.003 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmacotherapy in Psychiatry and Neurology, 2019. Verfasst von Justyna Suwała und 2 weiteren Autor:innen. Die Arbeit nennt 113 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Pharmacovigilance is an important aspect of depression treatment, considering that 40–90% of patients experience side effects of antidepressant use. This paper discusses the issues of optimising the use of venlafaxine, including its pharmacodynamic and pharmacokinetic properties, indications, adverse effects and risk factors for their occurrence, such as co-morbidities or genetic polymorphisms and interactions with other drugs.
Zitieren
APA
Suwała, J., Oleś, M., & Wiela-Hojeńska, A. (2019). Adverse effects of venlafaxine therapy and risk factors for their occurrence. Pharmacotherapy in Psychiatry and Neurology. https://doi.org/10.33450/fpn.2019.01.003
Vancouver
Suwała J, Oleś M, Wiela-Hojeńska A. Adverse effects of venlafaxine therapy and risk factors for their occurrence. Pharmacotherapy in Psychiatry and Neurology. 2019. doi:10.33450/fpn.2019.01.003
BibTeX
@article{Suwaa2019,
author = {Suwała, Justyna and Oleś, Marta and Wiela-Hojeńska, Anna},
title = {Adverse effects of venlafaxine therapy and risk factors for their occurrence},
journal = {Pharmacotherapy in Psychiatry and Neurology},
year = {2019},
doi = {10.33450/fpn.2019.01.003}
}
EUVIMED